4KB Stock Overview
A commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Krystal Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$168.00 |
| 52 Week High | US$196.40 |
| 52 Week Low | US$91.00 |
| Beta | 0.82 |
| 11 Month Change | 2.35% |
| 3 Month Change | -5.00% |
| 1 Year Change | 80.65% |
| 33 Year Change | 339.79% |
| 5 Year Change | n/a |
| Change since IPO | 182.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4KB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.1% | 0.8% | -0.4% |
| 1Y | 80.6% | -16.7% | 7.1% |
Return vs Industry: 4KB exceeded the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: 4KB exceeded the German Market which returned 7.1% over the past year.
Price Volatility
| 4KB volatility | |
|---|---|
| 4KB Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4KB has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 4KB's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 229 | Krish Krishnan | www.krystalbio.com |
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.
Krystal Biotech, Inc. Fundamentals Summary
| 4KB fundamental statistics | |
|---|---|
| Market cap | €4.89b |
| Earnings (TTM) | €49.96m |
| Revenue (TTM) | €230.41m |
100.1x
P/E Ratio21.7x
P/S RatioIs 4KB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4KB income statement (TTM) | |
|---|---|
| Revenue | US$241.52m |
| Cost of Revenue | US$17.98m |
| Gross Profit | US$223.54m |
| Other Expenses | US$171.16m |
| Earnings | US$52.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.82 |
| Gross Margin | 92.55% |
| Net Profit Margin | 21.68% |
| Debt/Equity Ratio | 0% |
How did 4KB perform over the long term?
See historical performance and comparison